

Journal of Nephrologist



Treatment of Henoch Schönlein nephritis; new trends

Azar Nickavar*

Department of Pediatric Nephrology, Iran University of Medical Sciences, Tehran, Iran

ARTICLE INFO

Article type:
Editorial

Article history:

Received: 15 June 2016
Accepted: 18 July 2016
Published online: 28 July 2016
DOI: 10.15171/jnp.2016.21

Keywords:

Henoch-Schönlein nephritis,
Chronic kidney disease, Endo-
capillary proliferation

Implication for health policy/practice/research/medical education:

Henoch-Schönlein purpura (HSP) is the most common small vessel vasculitis in children and adolescents with high incidence of renal involvement. Delayed and inappropriate management of severe Henoch-Schönlein nephritis is a major cause of chronic kidney disease. The most recent treatments of Henoch-Schönlein nephritis have been discussed in this editorial article.

Please cite this paper as: Nickavar A. Treatment of Henoch Schönlein nephritis; new trends. J Nephrologist. 2016;5(4):116-117. DOI: 10.15171/jnp.2016.21.

Editorial

Henoch-Schönlein purpura (HSP) was first described more than 200 years ago by Heberdon. It is the most common systemic vasculitis of childhood. Short and long term outcomes of HSP is generally favorable, with complete and spontaneous resolution of symptoms (1-3).

Renal involvement occurs in 40%-60% of pediatric patients within 4 to 6 weeks of the initial presentation (1). It is the major cause of mortality and morbidity in children with HSP (2) and prognosis is mainly dependent upon the severity of renal involvement (4).

Majority of patients with Henoch-Schönlein purpura nephritis (HSN) have a mild disease, presenting with hematuria and/or low-grade proteinuria, with a high recovery rate. A small percentage of patients present with nephrotic syndrome or renal function impairment (1,2).

A direct correlation has been suggested between the intensity of clinical manifestations, histopathologic grading, and renal outcome in HSN. There is a positive relationship between the severity of proteinuria, nephrotic syndrome and acute nephritis with both pathologic grading and scoring, particularly crescent formation, endocapillary proliferation, and tubular atrophy (2).

It has been suggested that older age at presentation, hypertension, increased serum creatinine, early onset nephritic, mixed nephritic-nephrotic syndrome at the onset of disease, extensive crescents, severity of glomerular necrosis and sclerosis, with tubulointerstitial

damage are the major risk factors of renal impairment in these patients (2,5).

Chronic kidney disease occurs in almost 20% of children admitted to the tertiary care centers (4). About 1%-7% of unselected patients with HSN may progress to end-stage renal disease by 20 years after diagnosis (1,6). However, early diagnosis, along with appropriate treatment and timely management improve eventual renal outcome in these patients (3).

There is no consensus for the treatment of HSN (1) and the most effective treatment remains controversial (7). It has been suggested that early corticosteroids treatment may not prevent the development of HSN and should not be routinely recommended (8,9).

Renal biopsy or immunosuppressive treatments is not recommended in patients with mild renal symptoms such as microhematuria, mild proteinuria and normal renal function which needs to regular follow up for the early detection of renal deterioration (1,3).

Data on the treatment of severe HSN are controversial and scarce (10). KDIGO guidelines recommended early treatment with angiotensin converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARBs) in patients with persistent proteinuria (1), to improve long term renal outcome independent of histologic lesions (11). A 6-month course of corticosteroid therapy is recommended in those with persistent proteinuria and glomerular filtration rate >50 mL/min per 1.73 m².

Early immunosuppressive therapy with high dose corticosteroids, cyclophosphamide, azathioprine (1)

*Corresponding author: Azar Nickavar, Department of Pediatric Nephrology, Iran University of Medical Sciences, Tehran, Iran. Email: anickavar@yahoo.com

calcineurin inhibitors (12), mycophenolate mofetil (MMF) (13), rituximab (3), mizoribine or methotrexate (1) have been suggested in patients with significant kidney involvement (proteinuria in nephrotic range and/or progressive kidney impairment) (3). The main objectives of immunosuppressive treatments are prevention of irreversible glomerular fibrosis with increasing proteinuria and improvement long term renal outcome (5,14).

In addition, combined immunosuppressive treatments with warfarin, dipyridamole, acetylsalicylic acid, tonsillectomy for eradication of chronic bacterial infections, hemoperfusion for elimination of immune mediators (3), intravenous immunoglobulin (IVIg) (5), plasma exchange for removal of inflammatory and procoagulant circulating complexes, antiplatelet drugs and vitamins have been suggested for treatment of HSN. However, there is not enough evidence about increased efficacy of immune suppression or multiple-drug treatment in children with severe HSN (1).

Conflicts of interest

The author declared no competing interests.

Author's contribution

AN was the single author of the manuscript.

Funding/Support

None

References

- Chen JY, Mao JH. Henoch-Schönlein purpura nephritis in children: incidence, pathogenesis and management. *World J Pediatr.* 2015;11(1):29-34. doi: 10.1007/s12519-014-0534-5.
- Nickavar A, Mehrazma M, Lahouti A. Clinicopathologic correlations in Henoch-Schönlein nephritis. *Iran J Kidney Dis.* 2012;6(6):437-40.
- Trnka P. Henoch-Schönlein purpura in children. *J Paediatr Child Health.* 2013;49(12):995-1003. doi: 10.1111/jpc.12403.
- Davin JC, Coppo R. Henoch-Schönlein purpura nephritis in children. *Nat Rev Nephrol.* 2014;10(10):563-73. doi: 10.1038/nrneph.2014.126.
- Nikibakhsh AA, Mahmoodzadeh H, Karamyiar M, Hejazi S, Noroozi M, Maccooie AA. Treatment of severe henoch-schonlein purpura nephritis with mycophenolate mofetil. *Saudi J Kidney Dis Transpl.* 2014;25(4):858-63.
- Pirojsakul K, Tangnararatchakit K, Chalermpanyakorn P, Tapaneya-Olarn W. Clinical outcome of children with Henoch-Schönlein purpura nephritis. *J Med Assoc Thai.* 2012;95(7):878-83.
- Ren P, Han F, Chen L, Xu Y, Wang Y, Chen J. The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch-Schönlein purpura nephritis. *Am J Nephrol.* 2012;36(3):271-7. doi: 10.1159/000341914.
- Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Hölttä T, et al. Outcome of Henoch-Schönlein purpura 8 years after treatment with a placebo or prednisone at disease onset. *Pediatr Nephrol.* 2012;27(6):933-9. doi: 10.1007/s00467-012-2106-z.
- Bluman J, Goldman RD. Henoch-Schönlein purpura in children: limited benefit of corticosteroids. *Can Fam Physician.* 2014;60(11):1007-10.
- Jauhola O, Ronkainen J, Autio-Harmainen H, Koskimies O, Ala-Houhala M, Arikoski P, et al. Cyclosporine A vs. methylprednisolone for Henoch-Schönlein nephritis: a randomized trial. *Pediatr Nephrol.* 2011;26(12):2159-66. doi: 10.1007/s00467-011-1919-5.
- Tudorache E, Azema C, Hogan J, Wannous H, Aoun B, Decramer S, et al. Even mild cases of paediatric Henoch-Schönlein purpura nephritis show significant long-term proteinuria. *Acta Paediatr.* 2015;104(8):843-8. doi: 10.1111/apa.12723.
- Ohara S, Kawasaki Y, Miyazaki K, Ono A, Suzuki Y, Suyama K, et al. Efficacy of cyclosporine A for steroid-resistant severe Henoch-Schönlein purpura nephritis. *Fukushima J Med Sci.* 2013;59(2):102-7.
- Du Y, Hou L, Zhao C, Han M, Wu Y. Treatment of children with Henoch-Schönlein purpura nephritis with mycophenolate mofetil. *Pediatr Nephrol.* 2012;27(5):765-71. doi: 10.1007/s00467-011-2057-9.
- Kawasaki Y. The pathogenesis and treatment of pediatric Henoch-Schönlein purpura nephritis. *Clin Exp Nephrol.* 2011;15(5):648-57. doi: 10.1007/s10157-011-0478-1.